Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
satralizumab + oral corticosteroids
- Development stage
- Unknown
- Lead developer
- Chugai Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Satralizumab + oral corticosteroids is a combination regimen used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), particularly in patients who are aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive. **Satralizumab** is a humanized IgG2 monoclonal antibody that targets both soluble and membrane-bound interleukin-6 (IL-6) receptors, thereby blocking IL-6-mediated signal transduction, reducing inflammation, and suppressing autoimmune activity[1][2][6][8]. **Oral corticosteroids** are synthetic analogs of glucocorticoids and act as anti-inflammatory and immunosuppressive agents by modulating gene expression to suppress multiple inflammatory cytokines and immune pathways. The combination is used to maximize relapse prevention and control autoimmune inflammation in NMOSD.
- Other names
- satralizumab + oral corticosteroids
02
Targets
GR (Glucocorticoid receptor)IL-6R (Interleukin-6 receptor subunit alpha)
Beyond the preview
Go deeper on satralizumab + oral corticosteroids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on satralizumab + oral corticosteroids.